- Home
- INKT vs LSB Comparison
INKT vs LSB Comparison
Compare INKT & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- LSB
- Stock Information
- Founded
- INKT 2017
- LSB 2002
- Country
- INKT United States
- LSB China
- Employees
- INKT N/A
- LSB N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- LSB
- Sector
- INKT Health Care
- LSB
- Exchange
- INKT Nasdaq
- LSB NYSE
- Market Cap
- INKT 31.2M
- LSB 31.5M
- IPO Year
- INKT 2021
- LSB N/A
- Fundamental
- Price
- INKT $7.03
- LSB $1.14
- Analyst Decision
- INKT Strong Buy
- LSB
- Analyst Count
- INKT 2
- LSB 0
- Target Price
- INKT $37.50
- LSB N/A
- AVG Volume (30 Days)
- INKT 2.8K
- LSB 17.6K
- Earning Date
- INKT 05-15-2025
- LSB 06-21-2025
- Dividend Yield
- INKT N/A
- LSB N/A
- EPS Growth
- INKT N/A
- LSB N/A
- EPS
- INKT N/A
- LSB N/A
- Revenue
- INKT N/A
- LSB $79,415,311.00
- Revenue This Year
- INKT N/A
- LSB $39.33
- Revenue Next Year
- INKT N/A
- LSB $75.61
- P/E Ratio
- INKT N/A
- LSB N/A
- Revenue Growth
- INKT N/A
- LSB N/A
- 52 Week Low
- INKT $4.56
- LSB $1.15
- 52 Week High
- INKT $13.79
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- INKT 39.71
- LSB 28.76
- Support Level
- INKT $7.20
- LSB $1.16
- Resistance Level
- INKT $7.40
- LSB $1.28
- Average True Range (ATR)
- INKT 0.39
- LSB 0.09
- MACD
- INKT -0.02
- LSB 0.02
- Stochastic Oscillator
- INKT 27.41
- LSB 0.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.